Cure of Hodgkin's Disease

Easson, E. C.; Russell, M. H.

doi:10.1136/bmj.2.5358.682-b

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, modern megavoltage radiotherapy, sometimes involving extensive prophylactic lymph node irradiation, has greatly improved survival rates in cases of seminoma testis, carcinoma cervix, localised lymphoma and Wilms' tumour. Indeed, it is only since largevolume irradiation has been employed that substantial cure rates have been reported in, for example, Hodgkin's disease (Easson and Russell, 1963), and failure to cure seminoma has become a rarity (Smithers, Wallace and Wallace, 1971). We have shown that a combination of radical surgery and postoperative irradiation in women with early medullary breast cancer, a tumour believed to be associated with a strong host reaction, achieved a corrected 20-year survival rate of virtually 100% (Bloom, Richardson and Field, 1970).…”

Section: Risk Of Treatment To Host Resistance?mentioning

confidence: 99%

Adjuvant Therapy for Adenocarcinoma of the Kidney: Present Position and Prospects1

Bloom

1973

British Journal of Urology

View full text Add to dashboard Cite

Section: Risk Of Treatment To Host Resistance?mentioning

confidence: 99%

Adjuvant Therapy for Adenocarcinoma of the Kidney: Present Position and Prospects1

Bloom

1973

British Journal of Urology

View full text Add to dashboard Cite

“…This is to be contrasted with a more modern conception of cure, which means that – thanks to some intervention – chances of disease resurgence have been significantly reduced. The definition by Easson and Russell [ 19 ], conceiving cure as disease-free survival over long duration, has been highly influential [ 19 ] c . The modern conception incorporates evidence-based uncertainty of outcome: you are cured where, on the best science available, there is a good chance that disease remission will continue.…”

Section: Discussionmentioning

confidence: 99%

“…c “… cure of a disease is taken to connote that in time – probably a decade or two after treatment – there remains a group of disease free survivors whose annual death rate from all causes is similar to that of a normal population group of the same sex and age distribution” [ 19 ].…”

Section: Endnotesmentioning

confidence: 99%

The ethics of talking about ‘HIV cure’

et al. 2015

View full text Add to dashboard Cite

BackgroundIn 2008, researchers reported that Timothy Brown (the ‘Berlin Patient’), a man with HIV infection and leukemia, received a stem-cell transplant that removed HIV from his body as far as can be detected. In 2013, an infant born with HIV infection received anti-retroviral treatment shortly after birth, but was then lost to the health care system for the next six months. When tested for HIV upon return, the child (the ‘Mississippi Baby’) had no detectable viral load despite cessation of treatment. These remarkable clinical developments have helped reinvigorate the field of ‘HIV cure’ research.DiscussionAlthough this research field is largely in a pre-clinical phase, talk about curing HIV has become a regular feature in the global mass media. This paper explores the language of HIV cure from philosophical, ethical and historical perspectives. Examination of currently influential definitions of ‘functional’ and ‘sterilizing’ HIV cure reveal that these conceptualizations are more complicated than they seem. Cure is often understood in narrowly biomedical terms in isolation from the social and psychological dimensions of illness. Contemporary notions of HIV cure also inherit some of the epistemic problems traditionally associated with cures for other health conditions, such as cancer. Efforts to gain greater conceptual clarity about cure lead to the normative question of how ‘HIV cure research’ ought to be talked about.SummaryWe argue that attention to basic concepts ethically matter in this context, and identify advantages as well as potential pitfalls of how different HIV/AIDS stakeholders may make use of the concept of cure. While concepts other than cure (such as remission) may be appropriate in clinical contexts, use of the word cure may be justified for other important purposes in the struggle against HIV/AIDS.

show abstract

“…The doses given during that era however, were low compared to the amounts delivered today, so HL was considered incurable. Peters (1950) reported a curable effect due to radiation alone, but it wasn't until with the introduction of the mantle field, also known as extended field radiation therapy (EFRT) in the early 1960's that definitive studies helped bring about widespread use of radiation for curative purposes of HL EFRT includes not only the gross tumor volume (GTV) but also the surrounding lymphatic pathways that are judged to be at risk of harboring subclinical disease (Kaplan, 1962, Easson andRussell, 1963). Further refinements of the radiation technique (Rosenberg and Kaplan, 1982) brought about the first ever decline in mortality rates of HL in the early 1970's (Devesa et al, 1987).…”

Section: -Historymentioning

confidence: 99%

SU‐C‐BRB‐01: Radiogenic Second Cancer Risk Differences in Female Hodgkin Lymphoma Patients Treated with Proton versus Photon Radiotherapies

et al. 2012

View full text Add to dashboard Cite

Purpose: To determine the significance of neutron and scatter dose in comparing the predicted risk of developing a radiogenic second cancer (RSC) to the breast and lungs of a female Hodgkin Lymphoma (HL) patient irradiated at 30 years old when treated with photon Intensity Modulated Radiotherapy (IMXT) versus Passive Scatter Proton Therapy (PSPT). Methods: Clinically approved IMXT and PSPT treatment plans were designed and prescribed 36 Gy to the treatment volume. For both plans, the therapeutic dose was calculated using a commercial treatment planning system (TPS). To account for inaccuracies in the TPS, the stray and neutron dose was calculated using an in‐house Monte Carlo code for IMXT and with an analytical model fit to Monte Carlo data for PSPT. The mean equivalent dose was calculated for the breasts and lungs for both techniques, input into the BEIR VII Excess Relative Risk (ERR) models, and RSC risk compared at subsequent 10 year intervals. Results: Mean dose to the patient's breast, including neutron and scatter dose, was 6.5 Sv for both the PSPT and IMXT plans which led to nearly equivalent ERR values. Sparing of the lungs was seen from PSPT (4.5 Sv) compared to the IMXT plan (8.4 Sv), however, which led to a reduction in ERR of nearly 50% for PSPT compared to IMXT. For the PSPT plan, the mean neutron equivalent dose contribution for the breast was 0.38 Sv (5% of the ERR contribution) and 0.28 Sv (6% of the ERR contribution) for the lungs. The IMXT plan had no neutron dose since it was planned with a 6 MV beam. Conclusions: Mean breast dose was nearly equivalent for both plans leading to equal ERR to the patient. The mean lung dose, however, was reduced by a factor of two for PSPT, even taking into account the dose from neutrons. Work supported by the National Cancer Institute (awards 1 RO1 CA131463‐01A1)

show abstract

Cure of Hodgkin's Disease

Cited by 9 publications

References 0 publications

Adjuvant Therapy for Adenocarcinoma of the Kidney: Present Position and Prospects1

Adjuvant Therapy for Adenocarcinoma of the Kidney: Present Position and Prospects1

The ethics of talking about ‘HIV cure’

SU‐C‐BRB‐01: Radiogenic Second Cancer Risk Differences in Female Hodgkin Lymphoma Patients Treated with Proton versus Photon Radiotherapies

Contact Info

Product

Resources

About